November 2008
Gut;Nov2008, Vol. 57 Issue 11, p1628
Academic Journal
The article presents the description of the endoscopic appearances in non-steroidal anti-inflammatory drug (NSAID)-related colopathy. Accordingly, there was no evidence that suggest collagenous colitis associated with tuberculous infection. NSAID-related colopathy is observed in several aspects including iron deficiency, abdominal pain, and weight loss. The possible mechanism of NSAID involves dysregulation of prostaglandin and leukotriene synthesis.


Related Articles

  • Dual Acting Anti-Inflammatory Drugs. Leone, S.; Ottani, A.; Bertolini, A. // Current Topics in Medicinal Chemistry;Feb2007, Vol. 7 Issue 3, p265 

    Drugs able to inhibit both cyclooxygenases (COX-1 and COX-2) and 5-lipoxygenase (5-LOX) (dual acting anti-inflammatory drugs) have been designed in order to obtain compounds that retain the activity of classical nonsteroidal anti-inflammatory drugs (NSAIDs) while avoiding their main drawbacks....

  • Antworten zu Wechselwirkung von Medikamentenmit der Grunderkrankung aus PRAXIS Nr. 6.  // Praxis (16618157);4/4/2012, Vol. 101 Issue 7, p493 

    No abstract available.

  • Modulation of the immediate allergic wheal reaction in the skin by drugs inhibiting the effects of leukotriene C4 and prostaglandin D2. Saarinen, J.; Harvima, R.; Horsmanheimo, M.; Harvima, I. // European Journal of Clinical Pharmacology;Apr2001, Vol. 57 Issue 1, p1 

    Objective: To study the effect of nordihydroguaiaretic acid (NDGA), zafirlukast and indomethacin on the size of the allergic prick-test wheal. Method: In the first part of the study, NDGA and indomethacin, as well as the mepyramine control (10 µg/ml and 100 µg/ml), were injected...

  • Inhibitors of Secretory Phospholipase A2 Group IIA. Reid, Robert C. // Current Medicinal Chemistry;2005, Vol. 12 Issue 25, p3011 

    Phospholipases A2 cleave membrane phospholipids to release arachidonic acid, the precursor to a large family of pro-inflammatory eicosanoids including prostaglandins and leukotrienes that have been proven to exacerbate numerous diseases that have an inflammatory component. Current therapies...

  • Anti-Inflammatory (Nonsteroidal) Drugs. Simeonova, Petia P.; Vohr, Hans-Werner // Encyclopedic Reference of Immunotoxicology;2005, p24 

    This article offers information about several anti-inflammatory or nonsteroidal drugs (NSAID). These drugs belong to a group of dissimilar agents which are used to treat various conditions. It has analgesic, anti-inflammatory and antipyretic properties. The characteristics of NSAID drugs are...

  • The Effect of Nonsteroidal Anti-Inflammatory Agents on Spinal Fusion. Thaller, John; Walker, Matthew; Kline, Alex J.; Anderson, D. Greg // Orthopedics;Mar2005, Vol. 28 Issue 3, p299 

    Discusses the effect of nonsteroidal anti-inflammatory agents (NSAIDS) on spinal fusion. Clinical efficacy of NSAIDS; Diagram that shows the process of forming prostaglandins, leukotrienes and thromboxanes from arachidonic acid; List of NSAIDS.

  • Pharmacotherapy -- first-line maintenance therapy.  // CMAJ: Canadian Medical Association Journal Supplement;9/1/2005, Vol. 173 Issue 6, pS28 

    Examines several studies concerning first-line maintenance therapy for asthma. Leukotriene receptor antagonists available in Canada; Results of trials which examined the efficacy of antagonists compared with placebo in the pediatric population; Efficacy of leukotriene receptor antagonists...

  • The Role of Leukotriene B4 in Neutrophil Infiltration in Experimentally-induced Inflammation of Rat Tooth Pulp. OKIJI, T.; MORITA, I.; SUNADA, I.; MUROTA, S. // Journal of Dental Research;Jan1991, Vol. 70 Issue 1, p34 

    Inflammation was induced in rat dental pulp by applying bacterial lipopolysaccharide (LPS). Extirpated tissue samples from inflamed pulps were incubated in vitro in a Krebs buffer containing Ca2+ ionophore A23187, and leukotriene (LT) B4 released into the medium was determined by...

  • Lumiracoxib537. Feret, Brett // Formulary;Sep2003, Vol. 38 Issue 9, p529 

    Reports on the marketing of non-steroidal anti-inflammatory drug lumiracoxib in the U.S. Treatment of arthritis and acute pain; Efficacy of the drug for treatment of osteoarthritis; Comparison of adverse effects to other COX-2 inhibitors. INSETS: Abstract;Formulary considerations.


Read the Article


Sign out of this library

Other Topics